Clinical Trial

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat people with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) that is CD19 positive using a medicine called MK-1045. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer. This trial will compare MK-1045 to a standard immunotherapy called blinatumomab. The goals of this trial are to learn if more people who receive MK-1045 have no cancer cells in their bone marrow compared to people who receive blinatumomab and if people who receive MK-1045 live longer compared to people who receive blinatumomab.
Protocol Amendment History 5 changes
notable Trial sites expanded: 12 -> 18 locations 2026-08-08
notable Trial sites expanded: 5 -> 9 locations 2026-07-11
notable Primary completion pushed: 2029-02-10 -> 2033-10-18 2026-06-06
minor Completion pushed: 2029-10-02 -> 2033-10-18 2026-06-06
critical Recruitment opened 2026-05-13
Trial Details
NCT Number NCT07570173
Lead Sponsor Merck Sharp & Dohme LLC
Conditions B-cell Acute Lymphoblastic Leukemia
Enrollment 340 participants
Start Date 2026-05-18
Primary Completion 2033-10-18 (estimated)
Study Completion 2033-10-18 (estimated)
Updated on ClinicalTrials.gov 2026-08-14